Clinically Tested
A clinical pilot investigation successfully validated the MecSense technology as a viable, non-invasive glucose monitoring solution for people with diabetes.
Clinical Pilot
MecSense conducted a clinical pilot investigation to validate the Non-Invasive Continuous Glucose Indicator (NCGI) technology. The study, approved by relevant Norwegian authorities, aimed to validate the technology and optimize the algorithm for signal analysis.
The study compared MecSense NCGI signals to Contour Next One strip-tests and data from Abbott Freestyle Libre and Dexcom. Preliminary analysis indicated that MecSense NCGI is a promising non-invasive technology with accuracy and sensitivity comparable to current glucose monitoring methods.
The clinical pilot investigation successfully validated the MecSense NCGI technology as a viable, non-invasive glucose monitoring solution for people with diabetes.
